Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.59 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.56 |
| ▸ | PPARG | P37231 | 7/20 | 0.56 |
| ▸ | PPARD | Q03181 | 7/20 | 0.56 |
| ▸ | PPARA | Q07869 | 7/20 | 0.56 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.56 |
| ▸ | TSHR | P16473 | 4/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | TLR2 | O60603 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.56 |
| ▸ | FABP4 | P15090 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.56 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | ESR1 | P03372 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | PDE4A | P27815 | 1/20 | 0.56 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8017577 | 0.92 | — | — | |
| Oxalic Acid SCHEMBL28834688 | 0.79 | AKR1B1 (0.59) | AKR1B1GPR84PPARGPPARDPPARA | |
| SCHEMBL7617367 | 0.79 | TSHR (0.63) | AKR1B1GPR84PPARGPPARDPPARA | |
| Oxalic Acid SCHEMBL28884528 | 0.77 | GPR84 (0.61) | AKR1B1GPR84PPARGPPARDPPARA | |
| SCHEMBL11459870 | 0.77 | CES1 (0.71) | GPR84PPARGPPARDPPARAHDAC11 | |
| Hexane SCHEMBL8125919 | 0.76 | AKR1B1 (0.61) | AKR1B1GPR84PPARGPPARDPPARA | |
| Hexane SCHEMBL6562722 | 0.76 | AKR1B1 (0.61) | AKR1B1GPR84PPARGPPARDPPARA | |
| Hexane SCHEMBL7487068 | 0.76 | AKR1B1 (0.61) | AKR1B1GPR84PPARGPPARDPPARA | |
| Hexane SCHEMBL6982515 | 0.76 | AKR1B1 (0.61) | AKR1B1GPR84PPARGPPARDPPARA | |
| Hexane SCHEMBL10688418 | 0.76 | AKR1B1 (0.61) | AKR1B1GPR84PPARGPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8211925-B2 | Benzamide glucokinase activators | TRANSTECH PHARMA, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-20110230529-A1 | BENZAMIDE GLUCOKINASE ACTIVATORS | TRANSTECH PHARMA, INC. (US) | 2011-09-22 | — | — | US | disclosed |
| US-7880012-B2 | e.g. 3-[2-(3-Isopropoxy-5-phenoxy-benzoylamino)-thiazol-5-yl-sulfanyl]-propionic acid methyl ester; metabolic disorder, blood glucose lowering, hyperglycemia, impaired glucose tolerance (IGT), Syndrome X, Polycystic Ovarian Syndrome, type I and type II diabetes, dyslipidemia, hyperlipidemia etc. | TRANSTECH PHARMA, INC. (US) | 2011-02-01 | — | — | US | disclosed |
| US-20100331379-A1 | BENZAMIDE GLUCOKINASE ACTIVATORS | VTVX HOLDINGS I LLC | 2010-12-30 | — | — | US | disclosed |
| EP-2019823-B1 | BENZAMIDE GLUCOKINASE ACTIVATORS | TRANSTECH PHARMA INC (US) | 2010-11-24 | — | — | EP | disclosed |
| US-20090176991-A1 | BENZAMIDE GLUCOKINASE ACTIVATORS | TRANSTECH PHARMA, LLC | 2009-07-09 | — | — | US | disclosed |
| EP-2019823-A2 | BENZAMIDE GLUCOKINASE ACTIVATORS | Transtech Pharma, Inc. (US) | 2009-02-04 | — | — | EP | disclosed |
| EP-2019824-A2 | BENZAMIDE GLUCOKINASE ACTIVATORS | Transtech Pharma, Inc. (US) | 2009-02-04 | — | — | EP | disclosed |
| WO-2007125105-A2 | BENZAMIDE GLUCOKINASE ACTIVATORS | TRANSTECH PHARMA, INC. (US) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007125103-A2 | BENZAMIDE GLUCOKINASE ACTIVATORS | TRANSTECH PHARMA, INC. (US) | 2007-11-08 | — | — | WO | disclosed |
| US-5620978-A | 8-aza, 6-aza and 6,8-diaza-1,4-dihydroquinoxaline-2,3-diones and the use thereof as antagonists for the glycine/NMDA receptor | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON, EUGENE OREGON (US) | 1997-04-15 | — | — | US | disclosed |
| US-5620979-A | TREATING NEURONAL LOSS ASSOCIATED WITH STROKE, ISCHEMIA, CENTRAL NERVOUS SYSTEM TRAUMA, HYPOGLYCEMIA OR SURGERY | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON, EUGENE OREGON (US) | 1997-04-15 | — | — | US | disclosed |
| EP-0743855-A1 | 8-AZA, 6-AZA AND 6,8-DIAZA-1,4-DIHYDROQUINOXALINE-2,3-DIONES AND THE USE THEREOF AS ANTAGONISTS FOR THE GLYCINE/NMDA RECEPTOR | ACEA PHARMACEUTICALS, INC. (US) | 1996-11-27 | — | — | EP | disclosed |
| EP-0732942-A1 | ALKYL, AZIDO, ALKOXY, AND FLUORO-SUBSTITUTED AND FUSED QUINOXALINEDIONES AND THE USE THEREOF AS GLYCINE RECEPTOR ANTAGONISTS | ACEA PHARMACEUTICALS, INC. (US) | 1996-09-25 | — | — | EP | disclosed |
| US-5514680-A | ANTICONVULSANTS WITH 5,6,7-TRISUBSTITUTED-1,4-DIHYDROQUINOXALINE-2,3-DIONE | THE STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY (US) | 1996-05-07 | — | — | US | disclosed |
| WO-1995018616-A2 | 8-AZA, 6-AZA AND 6,8-DIAZA-1,4-DIHYDROQUINOXALINE-2,3-DIONES AND THE USE THEREOF AS ANTAGONISTS FOR THE GLYCINE/NMDA RECEPTOR | ACEA PHARM INC (US) | 1995-07-13 | — | — | WO | disclosed |
| WO-1995012417-A1 | ALKYL, AZIDO, ALKOXY, AND FLUORO-SUBSTITUTED AND FUSED QUINOXALINEDIONES AND THE USE THEREOF AS GLYCINE RECEPTOR ANTAGONISTS | ACEA PHARMACEUTICALS, INC. (US) | 1995-05-11 | — | — | WO | disclosed |
| EP-0647137-A1 | GLYCINE RECEPTOR ANTAGONISTS AND THE USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1995-04-12 | — | — | EP | disclosed |
| WO-1994012029-A1 | USE OF FUSED RING CYCLOPENTANONES AND CYCLOPENTENONES IN CONTROLLING PLANT GROWTH | BRITISH TECHNOLOGY GROUP LIMITED (GB) | 1994-06-09 | — | — | WO | disclosed |
| WO-1994000124-A1 | GLYCINE RECEPTOR ANTAGONISTS AND THE USE THEREOF | WEBER ECKARD (US) | 1994-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176991-A1 | BENZAMIDE GLUCOKINASE ACTIVATORS | GCK, GCKR, KHK | AKR1B1 907/4885GPR84 1405/4885PPARG 225/4885 |
| US-20100331379-A1 | BENZAMIDE GLUCOKINASE ACTIVATORS | GCK, GCKR, HK2 | AKR1B1 1069/4885GPR84 1397/4885PPARG 242/4885 |
| US-20110230529-A1 | BENZAMIDE GLUCOKINASE ACTIVATORS | GCK, GCKR, KHK | AKR1B1 907/4885GPR84 1405/4885PPARG 225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.